甲胎蛋白放射免疫测定临床应用的探讨

本文报告了临床或病理确诊的98例原发性肝癌及269例非原发性肝癌疾患的血清AFP放射免疫测定结果。阳性率(>25ng/ml)分别为76.53％及28.25％原发性肝癌组AFP含量多呈高水平>400ng/ml升高,动态检测呈进行性升高或持续高水平。非原发性肝癌组则以低水平(25—200ng/ml)升高为主,超过肝癌阈值的(占7.81％)则多为一时性或在1—2个月内即恢复正常。AFP浓度的这种变化规律有助于两者的鉴别。并分析了原发性肝癌的AFP假阴性及非肝癌疾患的AFP呈高水平升高的可能因素,提出在临床应用中应注意综合分析及加强动态观察。

Discussion of Clinical Application of AFP-RIA

The results of AFP-RIA in 98 cases of primary hepatic cancer and 269 cases of other diseases are reported. The positve rates(serum AFP level: >25ng/ml)were 76.53％ and 28.25％ respectively. Most patients with primary hepatic cancer had a high AFP level (>400ng/ml). Dynamic determination showed a progressive increase in AFP level or its constant high level. In the cases without primary hepatic cancer, the serum AFP level was elevated with a low level (25—200ng/ml). Only 7.81％ patients had a high level of AFP, which showed a transient increase or returned to normal within one or two months. Such changes may help in the differentiation of primary hepatic cancer from non-neoplastic hepatic disease. The possible reasons of false positivity and false negativty of AFP are analysed.